Dr Marta Vaz Batista (Hospital Fernando Fonseca, Amadora, Portugal) discusses the preliminary results from the DEBBRAH phase II study, exploring trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement. These results were presented at the San Antonio Breast Cancer Symposium 2021.
Questions
1. Could you tell us a little about trastuzumab deruxtecan and its potential advantages over other trastuzumab antibody-drug conjugates? 00:20-01:49
2. What are the objectives of the DEBBRAH Phase II study? 01:49-02:55
3. Could you tell us a little about the study cohorts and eligibility criteria of the study? 02:55-03:58
4. What have been the preliminary findings of the study? 03:58-06:33
5. Where do you expect trastuzumab deruxtecan to sit in the treatment paradigm for HER2+ or HER2-low-expressing advanced breast cancer? 06:33-08:40
Speaker Disclosure: Marta Vaz Batista discloses honoraria from Daiichi Sankyo.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021
